A carregar...
The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
The tumor necrosis factor-α (TNF-α) golimumab (GLM), that is a fully human monoclonal anti-body, was registered in Russia in 2012 to treat rheumatic diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis. Its distinguishing characteristics are a high affinity fo...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado em: |
IMA-PRESS LLC
2014-12-01
|
| Colecção: | Современная ревматология |
| Assuntos: | |
| Acesso em linha: | https://mrj.ima-press.net/mrj/article/view/579 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|